The Future of Prostate Cancer Biomarkers Is Multiplexed


Combining urinary biomarkers improves clinical utility and provides a more robust evaluation

Combining urinary biomarkers allows a complete evaluation of prostate cancer cells while minimizing the risk of missing a foci of cancer or a unique mutation that drives clinical outcomes.

Here, we explore commercially available multiplex urine biomarkers for detecting prostate cancer.

Download the full infographic compliments of Clinical Lab Manager.

Download this free resource!